Yahoo Finance

Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg ...

HAMPTON, N.J., Nov. 05, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data from the Company’s Phase 1b study of barzolvolimab in prurigo nodularis (PN).
Benzinga.com

Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps

On Saturday, Incyte Corporation (NASDAQ:INCY) revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of ...
Yahoo Finance

Mayo Clinic Collaborates With PN Medical on a Research Study of Long COVID Patients

COCOA BEACH, FL / ACCESSWIRE / October 13, 2021 /PN Medical, a leading developer of cardiopulmonary training devices, is supporting Mayo Clinic in a clinical trial to identify new approaches to treat ...
The Globe and Mail

Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for ATTRv-PN

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Regeneron Pharmaceuticals and Intellia ...
Nasdaq

Protagonist (PTGX) Begins Dosing in Phase I Study With PN-235

Protagonist Therapeutics, Inc. PTGX announced that it has dosed the first patient in a phase I study, evaluating its oral interleukin-23 receptor (IL-23R) antagonist peptide – PN-235 (also known as ...